Eva M. Boorsma
YOU?
Author Swipe
View article: Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure Open
The effect of sodium‐glucose cotransporter‐2 (SGLT2) inhibitor ertugliflozin on fluid volume and kidney function was assessed in patients with type 2 diabetes and heart failure. Thirty‐four participants were randomized in this double‐blind…
View article: Efficacy and safety of low‐dose digoxin in patients with heart failure. Rationale and design of the DECISION trial
Efficacy and safety of low‐dose digoxin in patients with heart failure. Rationale and design of the DECISION trial Open
Aims Digoxin is the oldest drug in cardiovascular (CV) medicine, and one trial conducted >25 years ago showed a reduction in heart failure (HF) hospitalizations but no effect on mortality. However, later studies suggested that the dose of …
View article: Simplifying Treatment of Congestion
Simplifying Treatment of Congestion Open
View article: Characteristics and Clinical Outcomes of Patients Hospitalized for Acute Heart Failure Who Develop Atrial Fibrillation or Convert to Sinus Rhythm
Characteristics and Clinical Outcomes of Patients Hospitalized for Acute Heart Failure Who Develop Atrial Fibrillation or Convert to Sinus Rhythm Open
In patients hospitalized for AHF, only few converted from AF to sinus rhythm or sinus rhythm to AF. Although development of AF or persistent AF was associated with longer lengths of hospitalization, midterm mortality and readmission rates …
View article: Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome
Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome Open
Aim The comorbidities that collectively define metabolic syndrome are common in patients with heart failure. However, the role of metabolic syndrome in the pathophysiology of heart failure is not well understood. We therefore investigated …
View article: Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial
Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial Open
Circulating ketone body concentrations, and acetone in particular, were significantly higher during an episode of acute decompensated HF compared with after stabilization. Treatment with empagliflozin did not affect ketone body concentrati…
View article: Biomarker profiles and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome
Biomarker profiles and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome Open
Introduction The risk factors that collectively define metabolic syndrome (MetS) are common in heart failure (HF) patients. More research is needed to elucidate the individual role of MetS in the pathophysiology of HF. Purpose The study in…
View article: Albuminuria as a marker of systemic congestion in patients with heart failure
Albuminuria as a marker of systemic congestion in patients with heart failure Open
Aims Albuminuria is common in patients with heart failure and associated with worse outcomes. The underlying pathophysiological mechanism of albuminuria in heart failure is still incompletely understood. The association of clinical charact…
View article: Renal Compression in Heart Failure
Renal Compression in Heart Failure Open
View article: Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure
Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure Open
Background and objectives The estimated glomerular filtration rate (eGFR) is a crucial parameter in heart failure. Much less is known about the importance of tubular function. We addressed the effect of tubular maximum phosphate reabsorpti…
View article: Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure Open
View article: Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure Open
Aims Recently, dipeptidyl peptidase 3 (DPP3) has been discovered as the peptidase responsible for cleavage of angiotensin (1–7) [Ang (1–7)]. Ang (1–7) is part of the angiotensin‐converting enzyme–Ang (1–7)–Mas pathway which is considered t…
View article: Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure Open
Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors improve clinical outcome in patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet fully understood. We examined the effects of empagliflozin…
View article: Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment Open
View article: De onbesliste rol van digoxine bij stabiel hartfalen en atriumfibrilleren
De onbesliste rol van digoxine bij stabiel hartfalen en atriumfibrilleren Open
View article: Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF) Open
Aims Inhibition of sodium–glucose co‐transporter 2 (SGLT2) reduces the risk of death and heart failure (HF) admissions in patients with chronic HF. However, safety and clinical efficacy of SGLT2 inhibitors in patients with acute decompensa…
View article: Residual confounding in observational studies: new data from the old DIG trial
Residual confounding in observational studies: new data from the old DIG trial Open